RECRUITING

Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research is to determine if two proteins in the blood are increased during acute heart failure. These two proteins are produced when the heart becomes dysfunctional and unable to contract normally. They may then be released into the blood and be detected by standard method in the research laboratory. Thus, the purpose of this study is to determine the relation between the change of these two proteins in the blood and the occurrence of acute heart failure. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or heart failure.

Official Title

Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

Quick Facts

Study Start:2005-12
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00762008

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals aged \>18yrs
  2. * stable or decompensated heart failure, irrespective of LVEF
  3. * decompensated heart failure clinical symptoms such as dyspnea, rales, edema, elevated jugular venous pressure, or ascites
  4. * Imaging evidence of heart failure (cardiomegaly, poor contractile function or echocardiographic Doppler evidence of diastolic dysfunction or elevated right- or left-sided filling pressures)
  5. * Healthy individuals with no prior history of heart attack or heart failure will be recruited to use as controls.
  1. * Subjects who are unable to give informed consent
  2. * Subjects who had undergone cardiac or non-cardiac surgery in the 3 months before enrollment
  3. * Pregnant subjects are not excluded

Contacts and Locations

Study Contact

Fahad E Shah
CONTACT
860-679-2692
fshah@uchc.edu

Principal Investigator

Bruce T. Liang, M.D.
PRINCIPAL_INVESTIGATOR
UConn Health

Study Locations (Sites)

University of Connecticut Health Center
Farmington, Connecticut, 06030
United States

Collaborators and Investigators

Sponsor: UConn Health

  • Bruce T. Liang, M.D., PRINCIPAL_INVESTIGATOR, UConn Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2005-12
Study Completion Date2025-09

Study Record Updates

Study Start Date2005-12
Study Completion Date2025-09

Terms related to this study

Keywords Provided by Researchers

  • biomarkers

Additional Relevant MeSH Terms

  • Acute Decompensated Heart Failure
  • Heart Failure